Table 1 (A, B) Values for the half maximal inhibitory concentration (IC₅₀) and combination index (CI).

(A)
	IC₅₀	IC₅₀	IC₅₀	Combination
	BV6 (µM)	Olaparib (µM)	Olaparib + BV6 (µM)	Index*
UWB1289	1.36 ± 0.77	0.5 ± 0.1	0.3 ± 0.1	1.1 ± 0.05
UWB1289-RES	0.7 ± 0.1	11.7 ± 0.25	1.88 ± 0.4	0.6 ± 0.03
(B)
	IC₅₀ LCL161 (µM)	IC₅₀ Olaparib (µM)	IC₅₀ Olaparib + LCL161 (µM)	Combination Index*
UWB1289	11.7 ± .2.7	0.5 ± 0.1	4.9 ± 0.7	1.12 ± 0.03
UWB1289-RES	7 ± .0.5	11.7 ± 0.25	5.2 ± 0.3	0.76 ± 0.19
(C)
PDX model	Vehicle	Olaparib	Olaparib 100 mg/kg	LCL161	LCL161 + Olaparib	LCL161 + Olaparib 100 mg/kg
#56	71	43	78	78	92	>120
#62	18	36		22	36
#13	60	64		50	57
#931	25	32		43	36
#201	22	43		32	39
(D)
PDX model	Vehicle vs Olaparib	Vehicle vs LCL161	Olaparib vs LCL161	Vehicle vs LCL161 + Olaparib	Olaparib vs LCL161 + Olaparib	LCL161 vs LCL161 + Olaparib	Vehicle vs LCL161 + Olaparib 100 mg/kg	Olaparib 100 mg/kg vs LCL161 + Olaparib 100 mg/kg	LCL161 vs LCL161 + Olaparib 100 mg/kg
#56	0.3893	0.8643	0.2308	0.3881	0.0482*	0.3793	0.077	0.069	0.0204*
#62	0.0271*	0.4904	0.0929	0.0024**	0.7055	0.0070**
#13	0.4251	0.9893	0.4989	0.9676	0.5502	0.7305
#931	0.0724	0.0070**	0.1374	0.0040**	0.5751	0.1332
#201	0.2975	0.2233	0.1055	0.0926	0.8398	0.1241

The IC₅₀s and CIs (using the Chou–Talalay method) have been calculated for the PARP inhibitor olaparib and the IAP inhibitors BV6 and LCL161 in the BRCA1-mutated ovarian cancer cell line UWB1289 and the BRCA1-mutated ovarian cancer cell line with acquired resistance to olaparib UWB1289-RES.
(C) Median Time to Harvest (TTH) in days for HGSOC PDX models following treatment. Olaparib 50 mg/kg, unless otherwise indicated; LCL161 100 mg/kg.
(D) Comparison of response of HGSOC PDX models to treatment with olaparib (50 mg/kg), LCL161 (100 mg/kg) or combination treatment. P values were determined with the log-rank test, * indicates significance.

Search